Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect
Release Notes Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
ST12
MCID: SPP011
MIFTS: 61

Suppression of Tumorigenicity 12 (ST12)

Categories: Cancer diseases, Reproductive diseases
Data Licensing
For inquiries, contact:
[email protected]
Genes Variations Tissues Related diseases Publications Drugs
Sources

Aliases & Classifications for Suppression of Tumorigenicity 12

About this section

MalaCards integrated aliases for Suppression of Tumorigenicity 12:

Name: Suppression of Tumorigenicity 12 57
Prostate Adenocarcinoma 57 11 12 5 14 16
Adenocarcinoma of Prostate 71 33
Prostate Adenocarcinoma 1 57
St12 57
Pac1 57

Classifications:

MalaCards categories:
Global: Cancer diseases
Anatomical: Reproductive diseases
See all MalaCards categories (disease lists)
ICD11: 33


External Ids:

Disease Ontology 11 DOID:2526
OMIM® 57 601188
NCIt 49 C2919
SNOMED-CT 68 399490008
ICD11 33 1510677183
UMLS 71 C0007112
Sources

Summaries for Suppression of Tumorigenicity 12

About this section

Disease Ontology: 11 A prostate carcinoma that derives from epithelial cells of glandular origin.

MalaCards based summary: Suppression of Tumorigenicity 12, also known as prostate adenocarcinoma, is related to adenocarcinoma and prostate cancer. An important gene associated with Suppression of Tumorigenicity 12 is KLF6 (KLF Transcription Factor 6), and among its related pathways/superpathways are Gene expression (Transcription) and ERK Signaling. The drugs Fesoterodine and Lidocaine have been mentioned in the context of this disorder. Affiliated tissues include prostate, lymph node and bone marrow, and related phenotypes are Decreased viability and Increased shRNA abundance (Z-score > 2)

More information from OMIM: 601188
Sources

Related Diseases for Suppression of Tumorigenicity 12

About this section

Diseases related to Suppression of Tumorigenicity 12 via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 664)
# Related Disease Score Top Affiliating Genes
1 adenocarcinoma 32.0 TP53 SMAD4 PTEN PIK3CA MAP2K1 KLK3
2 prostate cancer 31.6 TP53 SPOP SMAD4 PTEN PIK3CA KLK3
3 small cell carcinoma 31.0 TP53 PTEN KLF6
4 transitional cell carcinoma 30.9 TP53 PTEN KLK3 ERBB2
5 papillary adenocarcinoma 30.8 TP53 HRAS ERBB2
6 meningioma, familial 30.8 TP53 PTEN PIK3CA IDH1 HRAS ERBB2
7 myeloma, multiple 30.7 TP53 PIK3CA LRRC56 IDH1 HRAS BRAF
8 mantle cell lymphoma 30.7 XPO1 TP53 PTEN ERBB2 CDKN2A AKT1
9 appendix adenocarcinoma 30.7 TP53 SMAD4 HRAS
10 bladder cancer 30.7 TP53 PTEN PIK3CA MAP2K1 LRRC56 KLK3
11 neuroblastoma 30.6 TP53 PTEN PIK3CA MAP2K1 HRAS ERBB2
12 cystadenocarcinoma 30.6 TP53 PTEN AKT1
13 colon adenocarcinoma 30.6 TP53 SMAD4 PIK3CA HRAS CTNNB1 BRAF
14 mismatch repair cancer syndrome 30.6 TP53 PTEN PIK3CA HRAS CTNNB1
15 sarcoma 30.6 TP53 PIK3CA HRAS CTNNB1 BRAF
16 adenoma 30.6 TP53 SMAD4 PIK3CA HRAS CTNNB1 CDKN2A
17 basal cell carcinoma 30.5 TP53 PTEN KLF6 CTNNB1 CDKN2A AKT1
18 glioma 30.5 TP53 PTEN PIK3CA IDH1
19 bladder adenocarcinoma 30.5 TP53 KLK3 CTNNB1
20 signet ring cell adenocarcinoma 30.5 TP53 HRAS ERBB2 CTNNB1
21 villous adenoma 30.5 TP53 SMAD4 HRAS CTNNB1
22 mucinous adenocarcinoma 30.5 TP53 SMAD4 PIK3CA HRAS ERBB2 CTNNB1
23 squamous cell carcinoma 30.5 TP53 SMAD4 PTEN PIK3CA HRAS ERBB2
24 clear cell adenocarcinoma 30.5 TP53 SMAD4 KLK3
25 melanoma 30.5 TP53 PTEN PIK3CA MAP2K1 LRRC56 HRAS
26 carcinosarcoma 30.4 TP53 PTEN PPP2R1A PIK3CA HRAS ERBB2
27 bladder urothelial carcinoma 30.4 TP53 PTEN PIK3CA MAP2K1 LRRC56 IDH1
28 lung cancer 30.4 TP53 SMAD4 PTEN PPP2R1A PIK3CA MAP2K1
29 renal cell carcinoma, nonpapillary 30.4 TP53 PTEN PIK3CA MAP2K1 HRAS ERBB2
30 leukemia, chronic lymphocytic 30.4 XPO1 TP53 PTEN LRRC56 HRAS ERBB2
31 neurofibroma 30.4 TP53 PTEN ERBB2 CDKN2A
32 penile benign neoplasm 30.4 TP53 PIK3CA CDKN2A
33 anal squamous cell carcinoma 30.4 TP53 PIK3CA CDKN2A
34 laryngeal benign neoplasm 30.4 TP53 PIK3CA CDKN2A
35 endometrial adenocarcinoma 30.4 TP53 PTEN CDKN2A AKT1
36 muir-torre syndrome 30.4 TP53 PTEN HRAS CDKN2A
37 rectal benign neoplasm 30.4 TP53 PIK3CA HRAS CTNNB1
38 plexiform neurofibroma 30.4 TP53 MAP2K1 HRAS CDKN2A
39 colonic benign neoplasm 30.4 TP53 SMAD4 PTEN PIK3CA HRAS ERBB2
40 penile cancer 30.4 TP53 PIK3CA CDKN2A
41 exanthem 30.4 HRAS ERBB2 AKT1
42 liposarcoma 30.4 TP53 PTEN PIK3CA CTNNB1 CDKN2A
43 lung benign neoplasm 30.3 TP53 HRAS CDKN2A
44 retinitis pigmentosa 11 30.3 TP53 PTEN CDKN2A AKT1
45 familial adenomatous polyposis 30.3 TP53 SMAD4 HRAS CTNNB1 BRAF
46 small cell cancer of the lung 30.3 TP53 PTEN PIK3CA KLK3 CDKN2A AKT1
47 thyroid tumor 30.3 PTEN PIK3CA LRRC56 HRAS BRAF AKT1
48 laryngeal squamous cell carcinoma 30.3 TP53 PTEN ERBB2 CDKN2A
49 pancreatic ductal carcinoma 30.3 TP53 SMAD4 HRAS ERBB2 CTNNB1 CDKN2A
50 plasma cell neoplasm 30.3 TP53 PIK3CA LRRC56 IDH1 HRAS BRAF

Graphical network of the top 20 diseases related to Suppression of Tumorigenicity 12:



Diseases related to Suppression of Tumorigenicity 12
Sources

Symptoms & Phenotypes for Suppression of Tumorigenicity 12

About this section

Clinical features from OMIM®:

601188 (Updated 08-Dec-2022)

GenomeRNAi Phenotypes related to Suppression of Tumorigenicity 12 according to GeneCards Suite gene sharing:

25 (show all 35)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-1 10.69 BRAF PIK3CA HRAS
2 Decreased viability GR00055-A-2 10.69 BRAF PIK3CA HRAS
3 Decreased viability GR00107-A-1 10.69 MAP2K1
4 Decreased viability GR00221-A-1 10.69 AKT1 CDKN2A PIK3CA HRAS
5 Decreased viability GR00221-A-2 10.69 AKT1 PIK3CA HRAS
6 Decreased viability GR00221-A-3 10.69 AKT1 CDKN2A ERBB2 HRAS MAP2K1
7 Decreased viability GR00221-A-4 10.69 AKT1 BRAF CDKN2A ERBB2 PIK3CA
8 Decreased viability GR00249-S 10.69 AKT1 BRAF
9 Decreased viability GR00301-A 10.69 BRAF
10 Decreased viability GR00381-A-1 10.69 BRAF
11 Decreased viability GR00402-S-2 10.69 PIK3CA
12 no effect GR00402-S-1 10.18 AKT1 BRAF CDKN2A CNOT9 CTNNB1 ERBB2
13 no effect GR00402-S-2 10.18 AKT1 BRAF CDKN2A CNOT9 CTNNB1 ERBB2
14 Increased shRNA abundance (Z-score > 2) GR00366-A-104 9.96 MED12
15 Increased shRNA abundance (Z-score > 2) GR00366-A-108 9.96 MED12
16 Increased shRNA abundance (Z-score > 2) GR00366-A-115 9.96 MED12
17 Increased shRNA abundance (Z-score > 2) GR00366-A-149 9.96 BRAF
18 Increased shRNA abundance (Z-score > 2) GR00366-A-153 9.96 MED12
19 Increased shRNA abundance (Z-score > 2) GR00366-A-185 9.96 MED12
20 Increased shRNA abundance (Z-score > 2) GR00366-A-190 9.96 MED12
21 Increased shRNA abundance (Z-score > 2) GR00366-A-213 9.96 AKT1
22 Increased shRNA abundance (Z-score > 2) GR00366-A-23 9.96 MED12
23 Increased shRNA abundance (Z-score > 2) GR00366-A-26 9.96 MED12
24 Increased shRNA abundance (Z-score > 2) GR00366-A-34 9.96 MED12
25 Increased shRNA abundance (Z-score > 2) GR00366-A-47 9.96 BRAF CTNNB1
26 Increased shRNA abundance (Z-score > 2) GR00366-A-60 9.96 AKT1 PIK3CA
27 Increased shRNA abundance (Z-score > 2) GR00366-A-70 9.96 AKT1 MED12
28 Increased shRNA abundance (Z-score > 2) GR00366-A-85 9.96 AKT1
29 Increased shRNA abundance (Z-score > 2) GR00366-A-89 9.96 MED12
30 Increased shRNA abundance (Z-score > 2) GR00366-A-9 9.96 MED12
31 Increased cell migration GR00055-A-1 9.67 CTNNB1
32 Increased cell migration GR00055-A-3 9.67 CTNNB1
33 Increased cell death in HCT116 cells GR00103-A-0 9.62 CTNNB1 PIK3CA PPP2R1A XPO1
34 Decreased viability in pancreas lineage GR00235-A 9.16 IDH1 TP53
35 Increased sensitivity to paclitaxel GR00112-A-0 8.96 SMAD4

MGI Mouse Phenotypes related to Suppression of Tumorigenicity 12:

45 (show all 20)
# Description MGI Source Accession Score Top Affiliating Genes
1 growth/size/body region MP:0005378 10.45 AKT1 BRAF CDKN2A CTNNB1 ERBB2 HRAS
2 homeostasis/metabolism MP:0005376 10.44 AKT1 BRAF CDKN2A CNOT9 CTNNB1 ERBB2
3 nervous system MP:0003631 10.42 AKT1 BRAF CDKN2A CNOT9 CTNNB1 ERBB2
4 neoplasm MP:0002006 10.37 AKT1 BRAF CDKN2A CTNNB1 ERBB2 HRAS
5 normal MP:0002873 10.36 AKT1 BRAF CTNNB1 ERBB2 HRAS KLK3
6 endocrine/exocrine gland MP:0005379 10.32 AKT1 BRAF CDKN2A CTNNB1 ERBB2 HRAS
7 muscle MP:0005369 10.31 AKT1 BRAF CDKN2A CTNNB1 ERBB2 HRAS
8 embryo MP:0005380 10.31 AKT1 BRAF CDKN2A CNOT9 CTNNB1 ERBB2
9 cardiovascular system MP:0005385 10.31 AKT1 BRAF CDKN2A CTNNB1 ERBB2 HRAS
10 cellular MP:0005384 10.25 AKT1 BRAF CDKN2A CTNNB1 ERBB2 KLF6
11 digestive/alimentary MP:0005381 10.18 BRAF CDKN2A CTNNB1 ERBB2 HRAS MAP2K1
12 behavior/neurological MP:0005386 10.18 AKT1 BRAF CDKN2A CTNNB1 ERBB2 HRAS
13 liver/biliary system MP:0005370 10.16 AKT1 BRAF CDKN2A CTNNB1 KLF6 PTEN
14 limbs/digits/tail MP:0005371 10.15 BRAF CTNNB1 ERBB2 MED12 PTEN SMAD4
15 craniofacial MP:0005382 10.06 BRAF CTNNB1 ERBB2 HRAS MAP2K1 MED12
16 reproductive system MP:0005389 10.03 AKT1 BRAF CDKN2A CTNNB1 ERBB2 KLF6
17 respiratory system MP:0005388 10.02 AKT1 BRAF CDKN2A CTNNB1 ERBB2 HRAS
18 skeleton MP:0005390 10 AKT1 BRAF CDKN2A CTNNB1 ERBB2 HRAS
19 mortality/aging MP:0010768 9.91 AKT1 BRAF CDKN2A CTNNB1 ERBB2 HRAS
20 integument MP:0010771 9.44 AKT1 BRAF CDKN2A CTNNB1 ERBB2 HRAS
Sources

Drugs & Therapeutics for Suppression of Tumorigenicity 12

About this section

Drugs for Suppression of Tumorigenicity 12 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 248)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Fesoterodine Approved Phase 4 286930-03-8, 286930-02-7 6918558
2
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
3
Prilocaine Approved Phase 4 721-50-6 4906
4 Neurotransmitter Agents Phase 4
5 Muscarinic Antagonists Phase 4
6 Cholinergic Antagonists Phase 4
7 Cholinergic Agents Phase 4
8 Anti-Arrhythmia Agents Phase 4
9 Sodium Channel Blockers Phase 4
10 Anesthetics, Local Phase 4
11 Anesthetics Phase 4
12 Diuretics, Potassium Sparing Phase 4
13
Iodine Approved, Investigational Phase 2, Phase 3 7553-56-2 807
14
Venlafaxine Approved Phase 3 99300-78-4, 93413-69-5 5656
15
Medroxyprogesterone acetate Approved, Investigational Phase 3 520-85-4, 71-58-9 6279 10631
16
Norepinephrine Approved Phase 3 51-41-2 439260
17
Cyproterone acetate Approved, Investigational Phase 3 427-51-0 9880
18
(R)-Bicalutamide Approved, Experimental Phase 3 90357-06-5, 113299-40-4 2375
19
Buserelin Approved, Investigational Phase 3 57982-77-1 42615 50225
20
Relugolix Approved, Investigational Phase 3 737789-87-6 10348973
21
Rucaparib Approved, Investigational Phase 3 283173-50-2 9931954
22
Flutamide Approved, Investigational Phase 2, Phase 3 13311-84-7 3397
23
Nilutamide Approved, Investigational Phase 2, Phase 3 63612-50-0 4493
24
Salicylic acid Approved, Investigational, Vet_approved Phase 2, Phase 3 69-72-7 338
25
Choline Approved, Nutraceutical Phase 3 62-49-7 305
26
Tryptophan Approved, Nutraceutical, Withdrawn Phase 3 73-22-3 6305
27
Cadexomer iodine Experimental Phase 2, Phase 3 94820-09-4
28
Bombesin Investigational Phase 2, Phase 3 31362-50-2 16133800
29
Cyproterone Phase 3 2098-66-0 5284537
30 Contraceptives, Oral, Hormonal Phase 3
31 Contraceptives, Oral Phase 3
32 Contraceptive Agents, Male Phase 3
33 Serotonin and Noradrenaline Reuptake Inhibitors Phase 3
34 Antimetabolites Phase 3
35 Hypolipidemic Agents Phase 3
36 Lipid Regulating Agents Phase 3
37 Pharmaceutical Solutions Phase 3
38 Nootropic Agents Phase 3
39 Hormone Antagonists Phase 3
40 Psychotropic Drugs Phase 3
41 Antidepressive Agents Phase 3
42 Contraceptive Agents Phase 3
43
Triptorelin Pamoate Phase 3
44 Nonsteroidal Anti-Androgens Phase 3
45 Hormones Phase 3
46 Androgens Phase 3
47 Androgen Antagonists Phase 3
48 Prolactin Release-Inhibiting Factors Phase 3
49 Gastrin-Releasing Peptide Phase 2, Phase 3 91976357
50
Serotonin Investigational, Nutraceutical Phase 3 50-67-9 5202

Interventional clinical trials:

(show top 50) (show all 273)
# Name Status NCT ID Phase Drugs
1 A Phase IV, Randomized, Double-Blind, Placebo-Controlled, Single-Center Study of the Effects of Fesoterodine in Men at High Risk for Overactive Bladder/Detrusor Overactivity Post Robotic-Assisted Laparoscopic Prostatectomy ) Completed NCT01661166 Phase 4 Fesoterodine;Placebo oral tablet
2 Impact of Local Anesthesia Type on Cancer Detection Rate in Transrectal Ultrasound Guided Prostate Biopsy Completed NCT02025361 Phase 4 intrarectal lidocaine gel;periprostatic nerve blockade
3 Comparison of High-dose- Versus Low-dose-rate Brachytherapy as Monotherapy in the Treatment of Early, Organ Confined Prostate Cancer. Unknown status NCT02258087 Phase 2, Phase 3
4 68Ga-PSMA-11 PET/MRI for Detection of Regional Nodal and Distant Metastases in Patients With Intermediate and High-Risk Prostate Cancer Completed NCT02678351 Phase 2, Phase 3 68Ga-PSMA-11
5 Efficacy and Tolerance of Cyproterone Acetate Versus Medroxyprogesterone Acetate Versus Venlafaxine LP in the Treatment of Hot Flushes Caused by Leuprorelin 11.25 mg in Patients Treated for a Prostate Adenocarcinoma Completed NCT01011751 Phase 3 Cyproterone acetate;Medroxyprogesterone acetate;Venlafaxine;Leuprorelin;Flutamide;Placebo
6 A Phase 3, Multi-Center, Open-Label Study to Assess the Diagnostic Performance and Clinical Impact of 18F-DCFPyL PET/CT Imaging Results in Men With Suspected Recurrence of Prostate Cancer Completed NCT03739684 Phase 3 18F-DCFPyL
7 68-Ga PSMA 11 PET/CT for Detection of Recurrent Prostate Cancer After Initial Therapy in Patients With Elevated PSA Completed NCT02673151 Phase 2, Phase 3 68Ga-PSMA-11
8 Staging of Untreated Patients With Very High-risk and High-risk Prostate Carcinoma Utilizing Hybrid C11-choline PET/MR and Pelvic Multiparametric MRI for Personalized Precise Treatment: a Pilot Study Completed NCT03404648 Phase 3 C-11 choline PET tracer;Gadobutrol
9 68Ga-PSMA-11 PET in Patients With Prostate Cancer Completed NCT05197257 Phase 3 Ga-PSMA-11
10 68Ga-PSMA PET/CT for Detection of Recurrent Prostate Cancer After Initial Therapy Completed NCT02940262 Phase 3
11 Phase III Multicenter Randomized Trial of Adjuvant Androgen Deprivation in Combination With Three-dimensional Conformal Radiotherapy Doses in High and Intermediate Risk Localized Prostate Cancer. Completed NCT02175212 Phase 3 Short term androgen deprivation;Long term androgen deprivation
12 Parallel Phase III Randomized Trials of Genomic-Risk Stratified Unfavorable Intermediate Risk Prostate Cancer: De-Intensification and Intensification Clinical Trial Evaluation (GUIDANCE) Recruiting NCT05050084 Phase 3 Bicalutamide;Buserelin;Darolutamide;Degarelix;Flutamide;Goserelin;Histrelin;Leuprolide;Relugolix;Triptorelin
13 Randomized Phase III Trial Incorporating Apalutamide and Advanced Imaging Into Salvage Treatment for Patients With Node-Positive Prostate Cancer After Radical Prostatectomy (INNOVATE*) *INtensifying Treatment for NOde Positive Prostate Cancer by VArying the Hormonal ThErapy Recruiting NCT04134260 Phase 3 Apalutamide;Hormone Therapy
14 CASPAR - A Phase III Trial of Enzalutamide and Rucaparib as a Novel Therapy in First-Line Metastatic Castration-Resistant Prostate Cancer Recruiting NCT04455750 Phase 3 Enzalutamide;Rucaparib camsylate;Placebo;Leuprolide Acetate;Goserelin Acetate;Degarelix
15 A Phase 3, Randomized, Open-Label, Controlled Study of Cabozantinib (XL184) in Combination With Atezolizumab vs Second Novel Hormonal Therapy (NHT) in Subjects With Metastatic Castration-Resistant Prostate Cancer Recruiting NCT04446117 Phase 3 Cabozantinib;Atezolizumab;Abiraterone Acetate;Enzalutamide;Prednisone
16 Phase III Study of Local or Systemic Therapy INtensification DIrected by PET in Prostate CAncer Patients With Post-ProstaTEctomy Biochemical Recurrence (INDICATE). Recruiting NCT04423211 Phase 3 Apalutamide;Goserelin Acetate;Leuprolide Acetate
17 Efficacy, Safety, and Pharmaco-kinetics of Leuprolide Acetate for Injection 3.75mg (Depot) (Leuprorelin) Administered in Subjects With Advanced Adenocarcinoma of Prostate: A Randomized, Active Controlled, Comparative, Open-Label, Multi-Center, Phase 3 Study Recruiting NCT04914195 Phase 3 Leuprolide Acetate 3.75 MG/ML
18 A Phase II Randomized Trial of MRI-Mapped Dose-Escalated Salvage Radiotherapy Post-Prostatectomy: The MAPS Trial Recruiting NCT01411345 Phase 2, Phase 3
19 Parallel Phase III Randomized Trials for High Risk Prostate Cancer Evaluating De-Intensification for Lower Genomic Risk and Intensification of Concurrent Therapy for Higher Genomic Risk With Radiation (PREDICT-RT*) Recruiting NCT04513717 Phase 3 Apalutamide;Bicalutamide;Buserelin;Degarelix;Flutamide;Goserelin;Histrelin;Leuprolide;Triptorelin
20 A Randomized Phase III Trial of Hypofractionated Post-prostatectomy Radiation Therapy (HYPORT) Versus Conventional Post-prostatectomy Radiation Therapy (COPORT) Active, not recruiting NCT03274687 Phase 3 Optional androgen deprivation therapy
21 Phase II-III Trial of Adjuvant Radiotherapy Following Radical Prostatectomy With or Without Adjuvant Docetaxel Active, not recruiting NCT03070886 Phase 2, Phase 3 Bicalutamide;Docetaxel;Flutamide;Goserelin Acetate;Leuprolide Acetate;Nilutamide
22 68Ga-RM2 PET/MRI in the Evaluation of Patients With Biochemical Recurrence of Prostate Cancer and Non-contributory CT Scans Active, not recruiting NCT02624518 Phase 2, Phase 3 Gallium Ga 68-labeled GRPR Antagonist BAY86-7548
23 Phase III IGRT and SBRT vs IGRT and Hypofractionated IMRT for Localized Intermediate Risk Prostate Cancer Active, not recruiting NCT03367702 Phase 3
24 A Randomized Phase III, Factorial Design, of Cabazitaxel and Pelvic Radiotherapy in Patients With Localized Prostate Cancer and High-risk Features of Relapse Active, not recruiting NCT01952223 Phase 3 Cabazitaxel
25 PALS: Prostate Cancer Active Lifestyle Study Terminated NCT02454517 Phase 3
26 Phase II Randomized Study to Ablate Oligometastatic Prostate Cancer by Single Dose Radiotherapy (SDRT) With or Without Adjuvant Systemic Therapy and to Characterize Its Molecular Phenotype Unknown status NCT04031378 Phase 2 Single Dose Radiotherapy (24 Gy) to all detectable lesions followed by adjuvant systemic therapy for 6 months
27 Hedgehog Inhibition as a Non-Castrating Approach to Hormone Sensitive Prostate Cancer: A Phase II Study of Itraconazole in Biochemical Relapse Completed NCT01787331 Phase 2 Itraconazole
28 A Phase II Neoadjuvant Study of Apalutamide, Abiraterone Acetate, Prednisone, Degarelix and Indomethacin in Men With Localized Prostate Cancer Pre-Prostatectomy Completed NCT02849990 Phase 2 Abiraterone Acetate;Apalutamide;Degarelix;Indomethacin;Prednisone
29 A Prospective Phase II Trial of Transperineal Ultrasound-Guided Brachytherapy for Locally Recurrent Prostate Adenocarcinoma Following External Beam Radiotherapy Completed NCT00450411 Phase 2
30 A Phase II Open Label Trial of Amifostine Plus Fractionated Radiotherapy for Primary Prostate Adenocarcinoma (T1a-T3b, NoMo, PSA>10 ng/ml) to Estimate Acute Grade 2 Genitourinary and Gastrointestinal Toxicity Completed NCT00003307 Phase 2 amifostine trihydrate
31 A Trial Of Neoadjuvant Androgen Supression And Dose Escalation Transperineal Ultrasound-Guided Brachytherapy For Locally Recurrent Prostate Adenocarcinoma Following External Beam Radiotherapy Completed NCT00032006 Phase 2
32 C11-Sodium Acetate PET/CT Imaging for Metastatic Disease in Intermediate-to-high Risk Prostate Adenocarcinoma Completed NCT01530269 Phase 2 C11-Sodium Acetate
33 Pentoxifylline, Atorvastatin, and Vitamin E (PAVE) as Treatment for Radiation-Induced Erectile Dysfunction Completed NCT03830164 Phase 2 Atorvastatin;Pentoxifylline
34 Evaluation of a 68Ga Small Molecule PSMA Antagonist Produced by Two Different Methods Completed NCT04685811 Phase 1, Phase 2 68Ga-PSMA-generator vs. 68Ga-PSMA-cyclotron
35 Evaluation of Hypoxia by PET With 18-FluoroMisonidazole During Radiation Therapy of Prostate Cancer Completed NCT01898065 Phase 2 18-F-MISO
36 A Phase II Randomized Study of Enzalutamide+Leuprolide Versus Enzalutamide+Leuprolide+Abiraterone Acetate+Prednisone as Neoadjuvant Therapy for HIgh-Risk Prostate Cancer Undergoing Prostatectomy Completed NCT02268175 Phase 2 Enzalutamide;Abiraterone Acetate;Prednisone;Leuprolide Acetate
37 A Pre-Operative Study to Assess the Effects of Apalutamide Plus LHRH Agonist or Apalutamide Plus Abiraterone Acetate Plus LHRH Agonist for Six Months for Prostate Cancer Patients at High Risk for Recurrence Completed NCT03279250 Phase 2 Abiraterone Acetate;Apalutamide;Prednisone
38 Biomarker-Driven Phase-2 Study of Combined Immune Checkpoint Blockade for AR-V7-Expressing Metastatic Castration-Resistant Prostate Cancer (STARVE-PC) Completed NCT02601014 Phase 2 Enzalutamide
39 Neoadjuvant Androgen Depletion in Combination With Vorinostat Followed by Radical Prostatectomy for Localized Prostate Cancer: Total Androgen-Receptor Gene Expression Targeted Therapy (TARGET) Completed NCT00589472 Phase 2 Bicalutamide;Goserelin Acetate;Leuprolide Acetate;Vorinostat
40 Gallium-68 PSMA-11 PET in Patients With Biochemical Recurrence Completed NCT03396874 Phase 2 68Ga-PSMA
41 A Phase II Pilot Study of Estramustine, Docetaxel, and Carboplatin for Patients With Hormone Refractory Prostate Cancer Progressing After Mitoxantrone-Based Chemotherapy. Completed NCT00183924 Phase 2 Estramustine;Docetaxel;Carboplatin
42 A Phase II Study of Trilostane for Androgen-Independent Prostate Cancer Completed NCT00181597 Phase 2 Trilostane;Hydrocortisone
43 A Phase II Immunotherapeutic Trial: Combination Androgen Ablative Therapy and CTLA-4 Blockade as a Treatment for Advanced Prostate Cancer Completed NCT00170157 Phase 2 Bicalutamide;Flutamide;Goserelin Acetate;Ipilimumab;Leuprolide Acetate
44 Modular Phase 2 Study to Link Combination Immune-therapy to Patients With Advanced Solid and Hematologic Malignancies. Module 9: PDR001 Plus LAG525 for Patients With Advanced Solid and Hematologic Malignancies. Completed NCT03365791 Phase 2
45 A Pilot Trial to Explore the Link Between Immunological Changes, Efficacy, Safety, and Tolerability of Durvalumab (MEDI4736) Plus Tremelimumab in Chemotherapy-Naïve Men With Metastatic Castration-Resistant Prostate Cancer (CRPC) Completed NCT03204812 Phase 2
46 A Randomized Phase II Study of Androgen Deprivation Combined With IMC-A12 Versus Androgen Deprivation Alone for Patients With New Hormone Sensitive Metastatic Prostate Cancer Completed NCT01120236 Phase 2 Bicalutamide;Goserelin Acetate;Leuprolide Acetate
47 Impact of 68GA-PSMA-11 PET/CT on Initial and Subsequent Treatment Strategies of Patients With Prostate Cancer Completed NCT04050215 Phase 2 Gallium Ga 68-labeled PSMA-11
48 Phase I/II Trial of Anti-IGF-IR Monoclonal Antibody IMC-A12 Plus mTOR Inhibitor Temsirolimus (CCI-779) in Metastatic Castration-Resistant Prostate Cancer (CRPC) Completed NCT01026623 Phase 1, Phase 2 Temsirolimus
49 Surgery Combined With IMRT-IGRT in Locally-advanced Prostate Cancers Completed NCT01148069 Phase 2
50 Phase IIA, Randomized Placebo-Controlled Trial of Single High Dose Cholecalciferol and Daily Genistein (G-2535) Versus Placebo in Men With Early Stage Prostate Cancer Undergoing Prostatectomy Completed NCT01325311 Phase 2 Cholecalciferol;Genistein

Search NIH Clinical Center for Suppression of Tumorigenicity 12

Sources

Genetic Tests for Suppression of Tumorigenicity 12

About this section
Sources

Anatomical Context for Suppression of Tumorigenicity 12

About this section

Organs/tissues related to Suppression of Tumorigenicity 12:

MalaCards : Prostate, Lymph Node, Bone Marrow, Bone, T Cells, Pituitary, Brain
Sources

Publications for Suppression of Tumorigenicity 12

About this section

Articles related to Suppression of Tumorigenicity 12:

(show top 50) (show all 4517)
# Title Authors PMID Year
1
Tumor suppression and apoptosis of human prostate carcinoma mediated by a genetic locus within human chromosome 10pter-q11. 62 57
8637912 1996
2
Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity. 5
26619011 2016
3
Solitary Scapular Metastasis as the First Presentation of Prostate Adenocarcinoma Identified on 99mTc-MDP SPECT/CT. 62
36469070 2023
4
Novel Ru(II)-bipyridine/phenanthroline-lapachol complexes as potential anti-cancer agents. 62
36155170 2022
5
Patient-reported Outcomes After External Beam Radiotherapy With Low Dose Rate Brachytherapy Boost vs Radical Prostatectomy for Localized Prostate Cancer: Five-year Results From a Prospective Comparative Effectiveness Study. 62
36006050 2022
6
68Ga-PSMA-11 PET/MRI in Patients with Newly Diagnosed Intermediate- or High-Risk Prostate Adenocarcinoma: PET Findings Correlate with Outcomes After Definitive Treatment. 62
35512996 2022
7
The 99mTc-MIP-1404 PSMA Uptake in the Isolated Paratracheal Lymph Node From the Prostate Adenocarcinoma. 62
36342797 2022
8
Stereotactic Magnetic Resonance-Guided Adaptive Radiation Therapy (SMART) for Abdominopelvic Oligometastases. 62
35598799 2022
9
The three-tails approach as a new strategy to improve selectivity of action of sulphonamide inhibitors against tumour-associated carbonic anhydrase IX and XII. 62
35306936 2022
10
Increased MYBL2 expression in aggressive hormone-sensitive prostate cancer. 62
36087093 2022
11
Deletion of monoamine oxidase A in a prostate cancer model enhances anti-tumor immunity through reduced immune suppression. 62
36242915 2022
12
Identification and validation of an E2F-related gene signature for predicting recurrence-free survival in human prostate cancer. 62
36471446 2022
13
Cribriform Lesions of the Prostate Gland. 62
36344177 2022
14
High-Grade Desmoplastic Foamy Gland Prostatic Adenocarcinoma. 62
36399606 2022
15
Deubiquitinase USP35 stabilizes BRPF1 to activate mevalonate (MVA) metabolism during prostate tumorigenesis. 62
36357379 2022
16
Continuous enzalutamide after progression of metastatic castration-resistant prostate cancer treated with docetaxel (PRESIDE): an international, randomised, phase 3b study. 62
36265504 2022
17
Detection and Genomic Characterisation of Clostridioides difficile from Spinach Fields. 62
36365061 2022
18
An unusual delayed rectal metastasis from prostate cancer masquerading as primary rectal cancer. 62
36252546 2022
19
Recurrent E. coli Urinary Tract Infections in Nursing Homes: Insight in Sequence Types and Antibiotic Resistance Patterns. 62
36421283 2022
20
[The role of expression of monocarboxylates of the first and fourth types (MCT1, MCT4) by tumor and stromal cells of prostate cancer in determining the prognosis and the efficiency of definitive treatment]. 62
36382820 2022
21
Isolated prostate amyloidosis; a case report. 62
36164377 2022
22
Impact of Left-Digit Age Bias in the Treatment of Localized Prostate Cancer. 62
35900150 2022
23
The crossroads of adenosinergic pathway and epithelial-mesenchymal plasticity in cancer. 62
35779713 2022
24
Establishment of an age- and tumor microenvironment-related gene signature for survival prediction in prostate cancer. 62
35535438 2022
25
Distribution of PACAP and PAC1 Receptor in the Human Eye. 62
35253081 2022
26
Small-molecule non-peptide antagonists of the PACAP receptor attenuate acute restraint stress-induced anxiety-like behaviors in mice. 62
36194909 2022
27
Inhibition of Src but not Syk causes weak reversal of GPVI-mediated platelet aggregation measured by light transmission aggregometry. 62
35535424 2022
28
PACAP and VIP Mitigate Rotenone-Induced Inflammation in BV-2 Microglial Cells. 62
35199308 2022
29
Cytological findings of metastatic poorly differentiated prostate adenocarcinoma to Virchow's node with immunohistochemical positivity for CD10 and negativity for PSA. 62
35557476 2022
30
Construction and validation of web-based nomograms for detecting and prognosticating in prostate adenocarcinoma with bone metastasis. 62
36329203 2022
31
A case of metastatic treatment-emergent small cell/neuroendocrine prostate cancer with BRCA2 mutation diagnosed by liver biopsy. 62
36341200 2022
32
Long-Term Outcomes of a Phase I Trial of Weekly Docetaxel, Total Androgen Blockade, and Image Guided Intensity Modulated Radiation Therapy for Localized High-Risk Prostate Adenocarcinoma. 62
36420198 2022
33
68 Ga-PSMA-11 PET/CT and PET/MRI in Rectal Linitis Plastica Secondary to Prostate Adenocarcinoma. 62
36327457 2022
34
Deciphering the enigma of neuroendocrine prostate cancer. 62
36317631 2022
35
Green Biosynthesis of Silver Nanoparticles Using Annona glabra and Annona squamosa Extracts with Antimicrobial, Anticancer, Apoptosis Potentials, Assisted by In Silico Modeling, and Metabolic Profiling. 62
36355526 2022
36
The NOGO receptor NgR2, a novel αVβ3 integrin effector, induces neuroendocrine differentiation in prostate cancer. 62
36344556 2022
37
18 F-FDG PET/CT in Urethral Metastases From Bladder Cancer. 62
35961619 2022
38
Bioinformatics analysis of prognostic value and immunological role of MeCP2 in pan-cancer. 62
36323715 2022
39
Fibromyxoid Nephrogenic Adenoma: A Series of 43 Cases Reassessing Predisposing Conditions, Clinical Presentation, and Morphology. 62
36395466 2022
40
Significance of Chr9p22.1-p21.3 Deletion in Cancer Development: A Pan-cancer In Silico Analysis. 62
36288884 2022
41
The germline mutational landscape of genitourinary cancers and its indication for prognosis and risk. 62
36451132 2022
42
Impact of TMPRSS2 Expression, Mutation Prognostics, and Small Molecule (CD, AD, TQ, and TQFL12) Inhibition on Pan-Cancer Tumors and Susceptibility to SARS-CoV-2. 62
36364238 2022
43
PAC1, VPAC1, and VPAC2 Receptor Expression in Rat and Human Trigeminal Ganglia: Characterization of PACAP-Responsive Receptor Antibodies. 62
36430275 2022
44
Incidental Detection of Radiotracer Uptake in Spindle Cell Lipoma on 18 F-PSMA PET/CT. 62
35619205 2022
45
Cartilage oligomeric matrix protein acts as a molecular biomarker in multiple cancer types. 62
36255654 2022
46
Preliminary Evaluation of 68Ga-P16-093, a PET Radiotracer Targeting Prostate-Specific Membrane Antigen in Prostate Cancer. 62
35349040 2022
47
Multi-Omics Analysis Reveals Clinical Value and Possible Mechanisms of ATAD1 Down-Regulation in Human Prostate Adenocarcinoma. 62
36362897 2022
48
Multiple Cavitary Lung Metastases from Prostate Adenocarcinoma. 62
36315854 2022
49
Prostate Adenocarcinoma Grade Group 1: Rationale for Retaining a Cancer Label in the 2022 World Health Organization Classification. 62
36202687 2022
50
Biological Dose Optimization for Particle Arc Therapy Using Helium and Carbon Ions. 62
35490991 2022
Sources

Variations for Suppression of Tumorigenicity 12

About this section

ClinVar genetic disease variations for Suppression of Tumorigenicity 12:

5 (show top 50) (show all 186)
# Gene Name Type Significance ClinVarId dbSNP ID Position
1 SPOP NM_001007228.2(SPOP):c.305T>G (p.Phe102Cys) SNV Likely Pathogenic
 161486 rs193920894 GRCh37: 17:47696643-47696643
GRCh38: 17:49619281-49619281
2 SPOP NM_001007228.2(SPOP):c.397T>G (p.Phe133Val) SNV Likely Pathogenic
 376545 rs1057519966 GRCh37: 17:47696426-47696426
GRCh38: 17:49619064-49619064
3 SPOP NM_001007228.2(SPOP):c.397T>A (p.Phe133Ile) SNV Likely Pathogenic
 376548 rs1057519966 GRCh37: 17:47696426-47696426
GRCh38: 17:49619064-49619064
4 SPOP NM_001007228.2(SPOP):c.260A>C (p.Tyr87Ser) SNV Likely Pathogenic
 376553 rs1057519971 GRCh37: 17:47696688-47696688
GRCh38: 17:49619326-49619326
5 SPOP NM_001007228.2(SPOP):c.391T>A (p.Trp131Arg) SNV Likely Pathogenic
 376551 rs1057519968 GRCh37: 17:47696432-47696432
GRCh38: 17:49619070-49619070
6 SPOP NM_001007228.2(SPOP):c.306C>G (p.Phe102Leu) SNV Likely Pathogenic
 376544 rs1057519965 GRCh37: 17:47696642-47696642
GRCh38: 17:49619280-49619280
7 SPOP NM_001007228.2(SPOP):c.392G>C (p.Trp131Ser) SNV Likely Pathogenic
 376550 rs1057519969 GRCh37: 17:47696431-47696431
GRCh38: 17:49619069-49619069
8 SPOP NM_001007228.2(SPOP):c.398T>G (p.Phe133Cys) SNV Likely Pathogenic
 376546 rs1057519967 GRCh37: 17:47696425-47696425
GRCh38: 17:49619063-49619063
9 SPOP NM_001007228.2(SPOP):c.259T>A (p.Tyr87Asn) SNV Likely Pathogenic
 376554 rs1057519972 GRCh37: 17:47696689-47696689
GRCh38: 17:49619327-49619327
10 SPOP NM_001007228.2(SPOP):c.393G>T (p.Trp131Cys) SNV Likely Pathogenic
 376552 rs1057519970 GRCh37: 17:47696430-47696430
GRCh38: 17:49619068-49619068
11 SPOP NM_001007228.2(SPOP):c.399C>G (p.Phe133Leu) SNV Likely Pathogenic
 161487 rs193921065 GRCh37: 17:47696424-47696424
GRCh38: 17:49619062-49619062
12 SPOP NM_001007228.2(SPOP):c.304T>G (p.Phe102Val) SNV Likely Pathogenic
 376543 rs1057519964 GRCh37: 17:47696644-47696644
GRCh38: 17:49619282-49619282
13 SPOP NM_001007228.2(SPOP):c.398T>C (p.Phe133Ser) SNV Likely Pathogenic
 376547 rs1057519967 GRCh37: 17:47696425-47696425
GRCh38: 17:49619063-49619063
14 SPOP NM_001007228.2(SPOP):c.391T>G (p.Trp131Gly) SNV Likely Pathogenic
 376549 rs1057519968 GRCh37: 17:47696432-47696432
GRCh38: 17:49619070-49619070
15 SPOP NM_001007228.2(SPOP):c.260A>G (p.Tyr87Cys) SNV Likely Pathogenic
 376555 rs1057519971 GRCh37: 17:47696688-47696688
GRCh38: 17:49619326-49619326
16 XPO1 NM_003400.4(XPO1):c.1712A>C (p.Glu571Ala) SNV Likely Pathogenic
 376697 rs1057520010 GRCh37: 2:61719471-61719471
GRCh38: 2:61492336-61492336
17 XPO1 NM_003400.4(XPO1):c.1712A>T (p.Glu571Val) SNV Likely Pathogenic
 376696 rs1057520010 GRCh37: 2:61719471-61719471
GRCh38: 2:61492336-61492336
18 XPO1 NM_003400.4(XPO1):c.1711G>A (p.Glu571Lys) SNV Likely Pathogenic
 376695 rs1057520009 GRCh37: 2:61719472-61719472
GRCh38: 2:61492337-61492337
19 MED12 NM_005120.3(MED12):c.3670C>G (p.Leu1224Val) SNV Likely Pathogenic
 376452 rs1057519912 GRCh37: X:70349258-70349258
GRCh38: X:71129408-71129408
20 PIK3CA NM_006218.4(PIK3CA):c.1624G>C (p.Glu542Gln) SNV Likely Pathogenic
 376244 rs121913273 GRCh37: 3:178936082-178936082
GRCh38: 3:179218294-179218294
21 PIK3CA NM_006218.4(PIK3CA):c.1625A>C (p.Glu542Ala) SNV Likely Pathogenic
 376473 rs1057519927 GRCh37: 3:178936083-178936083
GRCh38: 3:179218295-179218295
22 AKT1 NM_001382430.1(AKT1):c.49G>A (p.Glu17Lys) SNV Likely Pathogenic
 13983 rs121434592 GRCh37: 14:105246551-105246551
GRCh38: 14:104780214-104780214
23 CTNNB1 NM_001904.4(CTNNB1):c.121A>G (p.Thr41Ala) SNV Likely Pathogenic
 17580 rs121913412 GRCh37: 3:41266124-41266124
GRCh38: 3:41224633-41224633
24 CTNNB1 NM_001904.4(CTNNB1):c.122C>A (p.Thr41Asn) SNV Likely Pathogenic
 376394 rs121913413 GRCh37: 3:41266125-41266125
GRCh38: 3:41224634-41224634
25 PPP2R1A NM_014225.6(PPP2R1A):c.547C>G (p.Arg183Gly) SNV Likely Pathogenic
 376507 rs1057519946 GRCh37: 19:52715982-52715982
GRCh38: 19:52212729-52212729
26 BRAF NM_004333.6(BRAF):c.1790T>G (p.Leu597Arg) SNV Likely Pathogenic
 13968 rs121913366 GRCh37: 7:140453145-140453145
GRCh38: 7:140753345-140753345
27 BRAF NM_004333.6(BRAF):c.1803A>C (p.Lys601Asn) SNV Likely Pathogenic
 376286 rs121913365 GRCh37: 7:140453132-140453132
GRCh38: 7:140753332-140753332
28 PIK3CA NM_006218.4(PIK3CA):c.1034A>C (p.Asn345Thr) SNV Likely Pathogenic
 376489 rs1057519938 GRCh37: 3:178921552-178921552
GRCh38: 3:179203764-179203764
29 CTNNB1 NM_001904.4(CTNNB1):c.134C>A (p.Ser45Tyr) SNV Likely Pathogenic
 375895 rs121913409 GRCh37: 3:41266137-41266137
GRCh38: 3:41224646-41224646
30 MED12 NM_005120.3(MED12):c.3670C>T (p.Leu1224Phe) SNV Likely Pathogenic
 376451 rs1057519912 GRCh37: X:70349258-70349258
GRCh38: X:71129408-71129408
31 BRAF NM_004333.6(BRAF):c.1406G>T (p.Gly469Val) SNV Likely Pathogenic
 44803 rs121913355 GRCh37: 7:140481402-140481402
GRCh38: 7:140781602-140781602
32 PIK3CA NM_006218.4(PIK3CA):c.1034A>T (p.Asn345Ile) SNV Likely Pathogenic
 376488 rs1057519938 GRCh37: 3:178921552-178921552
GRCh38: 3:179203764-179203764
33 CNOT9 NM_005444.3(CNOT9):c.260C>G (p.Ser87Cys) SNV Likely Pathogenic
 376527 rs1057519957 GRCh37: 2:219447749-219447749
GRCh38: 2:218583026-218583026
34 PIK3CA NM_006218.4(PIK3CA):c.1625A>T (p.Glu542Val) SNV Likely Pathogenic
 376474 rs1057519927 GRCh37: 3:178936083-178936083
GRCh38: 3:179218295-179218295
35 PIK3CA NM_006218.4(PIK3CA):c.1634A>C (p.Glu545Ala) SNV Likely Pathogenic
 13659 rs121913274 GRCh37: 3:178936092-178936092
GRCh38: 3:179218304-179218304
36 ERBB2 NM_004448.4(ERBB2):c.2033G>A (p.Arg678Gln) SNV Likely Pathogenic
 376344 rs1057519862 GRCh37: 17:37879658-37879658
GRCh38: 17:39723405-39723405
37 CTNNB1 NM_001904.4(CTNNB1):c.134C>G (p.Ser45Cys) SNV Likely Pathogenic
 376242 rs121913409 GRCh37: 3:41266137-41266137
GRCh38: 3:41224646-41224646
38 CTNNB1 NM_001904.4(CTNNB1):c.134C>T (p.Ser45Phe) SNV Likely Pathogenic
 17588 rs121913409 GRCh37: 3:41266137-41266137
GRCh38: 3:41224646-41224646
39 BRAF NM_004333.6(BRAF):c.1802A>C (p.Lys601Thr) SNV Likely Pathogenic
 44818 rs397507484 GRCh37: 7:140453133-140453133
GRCh38: 7:140753333-140753333
40 PIK3CA NM_006218.4(PIK3CA):c.1033A>C (p.Asn345His) SNV Likely Pathogenic
 376490 rs1057519939 GRCh37: 3:178921551-178921551
GRCh38: 3:179203763-179203763
41 HRAS, LRRC56 NM_005343.4(HRAS):c.183G>T (p.Gln61His) SNV Likely Pathogenic
 376318 rs121913496 GRCh37: 11:533873-533873
GRCh38: 11:533873-533873
42 PIK3CA NM_006218.4(PIK3CA):c.263G>A (p.Arg88Gln) SNV Likely Pathogenic
 376049 rs121913287 GRCh37: 3:178916876-178916876
GRCh38: 3:179199088-179199088
43 PIK3CA NM_006218.4(PIK3CA):c.1633G>C (p.Glu545Gln) SNV Likely Pathogenic
 375896 rs104886003 GRCh37: 3:178936091-178936091
GRCh38: 3:179218303-179218303
44 PIK3CA NM_006218.4(PIK3CA):c.1634A>G (p.Glu545Gly) SNV Likely Pathogenic
 13656 rs121913274 GRCh37: 3:178936092-178936092
GRCh38: 3:179218304-179218304
45 MAP2K1 NM_002755.4(MAP2K1):c.171G>C (p.Lys57Asn) SNV Likely Pathogenic
 376174 rs869025608 GRCh37: 15:66727455-66727455
GRCh38: 15:66435117-66435117
46 BRAF NM_004333.6(BRAF):c.1790T>A (p.Leu597Gln) SNV Likely Pathogenic
 76687 rs121913366 GRCh37: 7:140453145-140453145
GRCh38: 7:140753345-140753345
47 CNOT9 NM_005444.3(CNOT9):c.259T>C (p.Ser87Pro) SNV Likely Pathogenic
 376526 rs1057519956 GRCh37: 2:219447748-219447748
GRCh38: 2:218583025-218583025
48 HRAS, LRRC56 NM_005343.4(HRAS):c.182A>T (p.Gln61Leu) SNV Likely Pathogenic
 376033 rs121913233 GRCh37: 11:533874-533874
GRCh38: 11:533874-533874
49 BRAF NM_004333.6(BRAF):c.1405G>C (p.Gly469Arg) SNV Likely Pathogenic
 13970 rs121913357 GRCh37: 7:140481403-140481403
GRCh38: 7:140781603-140781603
50 PIK3CA NM_006218.4(PIK3CA):c.1258T>G (p.Cys420Gly) SNV Likely Pathogenic
 376469 rs121913272 GRCh37: 3:178927980-178927980
GRCh38: 3:179210192-179210192
Sources

Expression for Suppression of Tumorigenicity 12

About this section
Search GEO for disease gene expression data for Suppression of Tumorigenicity 12.
Sources

Pathways for Suppression of Tumorigenicity 12

About this section

Pathways related to Suppression of Tumorigenicity 12 according to GeneCards Suite gene sharing:

(show top 50) (show all 157)
# Super pathways Score Top Affiliating Genes
1
Gene expression (Transcription) 66
Show member pathways
 14.17 XPO1 TP53 SMAD4 PTEN PPP2R1A MED12
2
ERK Signaling 64
Show member pathways
 13.94 TP53 SMAD4 PTEN PPP2R1A MAP2K1 HRAS
3
Disease 66
Show member pathways
 13.84 XPO1 TP53 SMAD4 PTEN PPP2R1A PIK3CA
4
Nervous system development 66
Show member pathways
 13.82 AKT1 CNOT9 CTNNB1 ERBB2 HRAS MAP2K1
5
GPCR Pathway 64
Show member pathways
 13.82 XPO1 TP53 SMAD4 PPP2R1A MAP2K1 HRAS
6
Signal Transduction 66
13.82 AKT1 BRAF CTNNB1 ERBB2 HRAS KLK3
7
MIF Mediated Glucocorticoid Regulation 64
Show member pathways
 13.73 TP53 SMAD4 PPP2R1A MAP2K1 HRAS ERBB2
8
TGF-Beta Pathway 64
Show member pathways
 13.66 AKT1 BRAF ERBB2 HRAS MAP2K1 PIK3CA
9
Prolactin Signaling 64
Show member pathways
 13.6 TP53 PTEN PIK3CA MAP2K1 HRAS ERBB2
10
Integrin Pathway 64
Show member pathways
 13.5 PTEN PIK3CA MAP2K1 HRAS CTNNB1 BRAF
11
RAF/MAP kinase cascade 66
Show member pathways
 13.47 AKT1 BRAF CTNNB1 ERBB2 HRAS MAP2K1
12
Nanog in Mammalian ESC Pluripotency 64
Show member pathways
 13.39 PPP2R1A MAP2K1 HRAS ERBB2 CTNNB1 BRAF
13
PIP3 activates AKT signaling 66
Show member pathways
 13.18 TP53 PTEN PPP2R1A PIK3CA ERBB2 AKT1
14
Phospholipase-C Pathway 64
Show member pathways
 13.18 TP53 PTEN MAP2K1 HRAS BRAF AKT1
15
PI3K-Akt signaling pathway 74
Show member pathways
 13.09 AKT1 HRAS MAP2K1 PIK3CA PPP2R1A PTEN
16
Regulation of TP53 Activity 66
Show member pathways
 13.08 TP53 PTEN PPP2R1A CNOT9 CDKN2A AKT1
17
Sertoli-Sertoli Cell Junction Dynamics 64
Show member pathways
 13.07 AKT1 BRAF CTNNB1 HRAS MAP2K1 PPP2R1A
18
TNFR1 Pathway 64
Show member pathways
 13.05 TP53 PTEN PIK3CA MAP2K1 HRAS CDKN2A
19
Beta-Adrenergic Signaling 64
Show member pathways
 13.04 PPP2R1A PIK3CA MAP2K1 KLK3 HRAS CTNNB1
20
NFAT and Cardiac Hypertrophy 64
Show member pathways
 13 PTEN PIK3CA MAP2K1 HRAS ERBB2 BRAF
21
IL-9 Signaling Pathways 65
Show member pathways
 12.99 PTEN PIK3CA MAP2K1 HRAS BRAF AKT1
22
Toll-like receptor signaling pathway 74
Show member pathways
 12.99 TP53 SMAD4 PIK3CA MAP2K1 HRAS BRAF
23
Signaling by Receptor Tyrosine Kinases 66
12.98 PPP2R1A PIK3CA MAP2K1 HRAS ERBB2 CTNNB1
24
Alzheimer's disease and miRNA effects 74
Show member pathways
 12.97 PIK3CA MAP2K1 HRAS CTNNB1 BRAF AKT1
25
CCR5 Pathway in Macrophages 64
Show member pathways
 12.95 PIK3CA MAP2K1 HRAS BRAF AKT1
26
Development Angiotensin activation of ERK 22
Show member pathways
 12.95 PIK3CA MAP2K1 HRAS BRAF AKT1
27
fMLP Pathway 64
Show member pathways
 12.88 TP53 MAP2K1 HRAS CTNNB1 AKT1
28
Translation Insulin regulation of translation 22
Show member pathways
 12.86 AKT1 HRAS MAP2K1 PIK3CA PTEN
29
4-1BB Pathway 64
Show member pathways
 12.81 TP53 PPP2R1A MAP2K1 HRAS BRAF AKT1
30
Malignant pleural mesothelioma 74
12.81 TP53 PTEN PIK3CA MAP2K1 HRAS CTNNB1
31
PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling 66
Show member pathways
 12.8 PTEN PPP2R1A PIK3CA ERBB2 AKT1
32
G-protein signaling G-Protein alpha-i signaling cascades 22
Show member pathways
 12.79 MAP2K1 HRAS CTNNB1 BRAF AKT1
33
G-Beta Gamma Signaling 64
Show member pathways
 12.78 MAP2K1 HRAS CDKN2A BRAF AKT1
34
Overview of interferons-mediated signaling pathway 74
Show member pathways
 12.76 TP53 PPP2R1A PIK3CA MAP2K1 HRAS AKT1
35
Immune response IL-23 signaling pathway 22
Show member pathways
 12.73 AKT1 CTNNB1 ERBB2 HRAS PIK3CA TP53
36
Signaling by NTRKs 66
Show member pathways
 12.69 PPP2R1A PIK3CA MAP2K1 HRAS BRAF
37
Cytoskeleton remodeling Regulation of actin cytoskeleton by Rho GTPases 22
Show member pathways
 12.67 MAP2K1 HRAS CTNNB1 AKT1
38
Angiopoietin-like protein 8 regulatory pathway 74
Show member pathways
 12.66 PTEN PIK3CA MAP2K1 HRAS AKT1
39
NF-kappaB Pathway 70
Show member pathways
 12.58 TP53 PIK3CA MAP2K1 HRAS ERBB2 CTNNB1
40
Development Dopamine D2 receptor transactivation of EGFR 22
Show member pathways
 12.56 XPO1 PIK3CA MAP2K1 HRAS AKT1
41
Development VEGF signaling via VEGFR2 - generic cascades 22
Show member pathways
 12.56 PIK3CA MAP2K1 HRAS CTNNB1 BRAF AKT1
42
Development EGFR signaling pathway 22
Show member pathways
 12.56 TP53 PIK3CA MAP2K1 HRAS ERBB2 CTNNB1
43
MAPK signaling pathway 74
12.55 TP53 MAP2K1 HRAS BRAF AKT1
44
G-protein signaling RAC1 in cellular process 22
Show member pathways
 12.53 BRAF CTNNB1 ERBB2 HRAS MAP2K1 PIK3CA
45
Development FGFR signaling pathway 22
Show member pathways
 12.52 PIK3CA MAP2K1 HRAS AKT1
46
Endometrial cancer 74
Show member pathways
 12.52 AKT1 BRAF CDKN2A CTNNB1 ERBB2 HRAS
47
CD28 co-stimulation 66
Show member pathways
 12.49 PPP2R1A PIK3CA CTNNB1 AKT1
48
Immune response Fc epsilon RI pathway 22
Show member pathways
 12.48 PTEN PIK3CA MAP2K1 HRAS AKT1
49
Development A3 receptor signaling 22
Show member pathways
 12.48 PIK3CA MAP2K1 HRAS CTNNB1 AKT1
50
Cell cycle Regulation of G1/S transition (part 1) 22
Show member pathways
 12.47 XPO1 SMAD4 PPP2R1A CDKN2A
Sources

GO Terms for Suppression of Tumorigenicity 12

About this section

Cellular components related to Suppression of Tumorigenicity 12 according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein-containing complex GO:0032991 9.44 XPO1 TP53 SMAD4 KLK3 CTNNB1 CNOT9

Biological processes related to Suppression of Tumorigenicity 12 according to GeneCards Suite gene sharing:

(show all 21)
# Name GO ID Score Top Affiliating Genes
1 negative regulation of cell population proliferation GO:0008285 10.28 CDKN2A CTNNB1 HRAS MAP2K1 PTEN SMAD4
2 negative regulation of gene expression GO:0010629 10.24 TP53 PIK3CA HRAS CTNNB1 AKT1
3 positive regulation of DNA-templated transcription GO:0045893 10.19 AKT1 CDKN2A CNOT9 CTNNB1 KLF6 MAP2K1
4 MAPK cascade GO:0000165 10.18 BRAF CTNNB1 HRAS MAP2K1
5 negative regulation of cell growth GO:0030308 10.15 CDKN2A PPP2R1A SMAD4 TP53
6 phosphorylation GO:0016310 10.13 PIK3CA MAP2K1 ERBB2 CDKN2A BRAF AKT1
7 thymus development GO:0048538 10.08 MAP2K1 CTNNB1 BRAF
8 positive regulation of peptidyl-serine phosphorylation GO:0033138 10.08 PIK3CA CNOT9 BRAF AKT1
9 epidermal growth factor receptor signaling pathway GO:0007173 10.07 PIK3CA BRAF AKT1
10 heart development GO:0007507 10.07 CTNNB1 ERBB2 MAP2K1 MED12 PTEN TP53
11 cell population proliferation GO:0008283 10.04 AKT1 CTNNB1 PTEN SMAD4 TP53
12 T cell differentiation in thymus GO:0033077 10.03 TP53 CTNNB1 BRAF
13 cellular senescence GO:0090398 10.01 TP53 MAP2K1 HRAS CDKN2A
14 positive regulation of gene expression GO:0010628 9.97 TP53 MAP2K1 HRAS ERBB2 CTNNB1 CDKN2A
15 phosphatidylinositol 3-kinase signaling GO:0014065 9.92 PTEN PIK3CA ERBB2 AKT1
16 embryonic organ development GO:0048568 9.84 TP53 MED12 CTNNB1
17 insulin-like growth factor receptor signaling pathway GO:0048009 9.76 PIK3CA MAP2K1 AKT1
18 negative regulation of immature T cell proliferation in thymus GO:0033088 9.74 ERBB2 CDKN2A
19 cellular response to decreased oxygen levels GO:0036294 9.69 PTEN AKT1
20 regulation of axon regeneration GO:0048679 9.26 PTEN MAP2K1 BRAF
21 regulation of cell population proliferation GO:0042127 9.23 TP53 SMAD4 HRAS ERBB2 CTNNB1 BRAF

Molecular functions related to Suppression of Tumorigenicity 12 according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 kinase activity GO:0016301 9.56 PIK3CA MAP2K1 ERBB2 CDKN2A BRAF AKT1
2 disordered domain specific binding GO:0097718 9.55 TP53 CTNNB1 CDKN2A
3 protein C-terminus binding GO:0008022 9.32 MED12 MAP2K1 HRAS ERBB2 CTNNB1
Sources

Sources for Suppression of Tumorigenicity 12

About this section
2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....